Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 9M | 10M | 64M | 77M | 75M |
| Gross Profit | 674K | 600K | 23M | 27M | 33M |
| Operating Income | 405K | 313K | 7M | 15M | 19M |
| EBITDA | 342K | 527K | 6M | 15M | 19M |
| Net Income | 266K | 273K | 5M | 12M | 15M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.047
-6.00% today
1Y Change
-38.18%
Window
Jun 23, 2025 → Jun 5, 2026
Coverage: 240 bars · Jun 23, 2025 → Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rafarma Pharmaceuticals, Inc. (RAFA) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.05 and down 38.2% across the available one-year price window (Jun 23, 2025 → Jun 5, 2026). Baseline metrics include revenue growth of +1.1%, EPS growth of +33.3%, a dividend yield of 0.0%. What stands out right now is revenue +1.1%, EPS +33.3%, free cash flow 0.0% with operating margin 4.1% and ROIC 2.4%. Valuation is more restrained than many high-expectation growth names at P/E 25.0 and price/sales 0.6. Stock Foundry combines RAFA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RAFA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RAFA Max Drawdown
-72.73%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RAFA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$74.7M
-3.5% YoY
FY Net Income
$14.8M
+28.3% YoY
Free Cash Flow
-$8.8M
-404.6% YoY
Revenue Growth
+1.1%
EPS Growth
+33.3%
Gross Margin
6.4%
Net Margin
2.5%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 9M | 10M | 64M | 77M | 75M |
| Gross Profit | 674K | 600K | 23M | 27M | 33M |
| Operating Income | 405K | 313K | 7M | 15M | 19M |
| EBITDA | 342K | 527K | 6M | 15M | 19M |
| Net Income | 266K | 273K | 5M | 12M | 15M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 77K | 66K | 18M | 14M | 5M |
| Total Assets | 12M | 12M | 98M | 89M | 71M |
| Total Liabilities | 2M | 2M | 20M | 20M | 19M |
| Shareholder Equity | 10M | 11M | 78M | 70M | 52M |
| Total Debt | 0 | 0 | 909K | 2M | 496K |
| Net Debt | -77K | -66K | -17M | -12M | -5M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
9M
-404.6% YoY
Capital Expenditures
0
Free Cash Flow
9M
-404.6% YoY
Key ratios
Gross Margin
6.4%
Operating Margin
4.1%
Net Margin
2.5%
ROE
2.1%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.